Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.
Less than two years after setting up its BI X digital lab, Boehringer Ingelheim is ready to start clinical trials of a programme monitoring speech patterns to diagnose…
A successful Mylan challenge would see generic entry within two years – though Biogen has fought off copycats before.
With rich countries like the US finding it hard to fund gene therapies, it is worth asking whether these projects will ever reach patients in developing countries. And if…
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
Business development decisions have started the clock on a financial time bomb set to go off within the next three months.
Targeting a mechanism of resistance to first-generation BTK inhibitors has caught the attention of biotechs like Arqule, which claimed a major success last week.
Three gene therapy contenders, Abeona, Fibrocell and Krystal, are taking different approaches in the quest to cure epidermolysis bullosa.
The J&J-Auris tie-up will yield a huge return for investors who went in big.